Medical technology company Glucotrack has achieved a significant milestone in diabetes management with its first-in-human study of an intravascular continuous blood glucose monitoring (CBGM) system. The study, conducted at InCor Hospital in São Paulo, Brazil, evaluated the safety and technical feasibility of a potentially groundbreaking device designed to address critical challenges in diabetes care.
The trial involved six adult participants with insulin-dependent diabetes and demonstrated promising results. Researchers achieved 99% data capture and a Mean Absolute Relative Difference of 6.7% when comparing the device's readings to traditional fingerstick blood glucose monitors. Notably, the study met its primary safety endpoint with no serious adverse events reported.
Current continuous glucose monitoring technologies often rely on measuring interstitial fluid, which can introduce delays in glucose level tracking. In contrast, Glucotrack's CBGM system measures glucose directly from the blood, potentially offering more accurate and real-time readings. The device is designed to be fully implantable, discreet, and capable of functioning for multiple years with minimal calibration requirements.
Following the successful initial study, Glucotrack is preparing to launch a long-term outside-the-United-States clinical trial. This multicenter study will enroll up to 30 participants and assess the commercial version of the CBGM system over one year, with potential extension to three years. The research aims to validate the device's safety, performance, and usability in real-world conditions.
With approximately 38.4 million Americans living with diabetes, innovative monitoring technologies could significantly improve patient care and management. Glucotrack's approach represents a potential paradigm shift in how patients track and respond to blood glucose fluctuations, offering hope for more precise and less invasive diabetes management.
